- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05939128
En icke-interventionell prospektiv studie av tidig HER2-negativ högriskbröstcancer och BRCA1/2-mutationsprevalens i Ryssland (ERA)
En multicenter, singelarm, icke-interventionell, observationell, prospektiv studie för att bedöma BRCA1/2m-prevalensen, behandlingsmetoder och resultat hos HER2-negativa högriskpatienter med tidig bröstcancer i Ryssland
(Neo)adjuvant treatment approaches and outcomes
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
Arkhangelsk, Ryssland
- Research Site
-
Barnaul, Ryssland
- Research Site
-
Belgorod, Ryssland
- Research Site
-
Chelyabinsk, Ryssland
- Research Site
-
Grozny, Ryssland
- Research Site
-
Irkutsk, Ryssland
- Research Site
-
Khanty-Mansiysk, Ryssland
- Research Site
-
Krasnodar, Ryssland
- Research Site
-
Krasnoyarsk, Ryssland
- Research Site
-
Moscow, Ryssland
- Research Site
-
Nal'chik, Ryssland
- Research Site
-
Nyzhny Novgorod, Ryssland
- Research Site
-
Ryazan, Ryssland
- Research Site
-
Saint Petersburg, Ryssland
- Research Site
-
Severodvinsk, Ryssland
- Research Site
-
Sochi, Ryssland
- Research Site
-
Ufa, Ryssland
- Research Site
-
Vladivostok, Ryssland
- Research Site
-
Yaroslavl, Ryssland
- Research Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Study population will consist of early breast cancer HER2-negative patients with high risk of recurrence with available medical history, surgery or biopsy FFPE from primary tumor. It is estimated that approximately 750 patients will be enrolled in approximately 25 sites
Beskrivning
Inclusion Criteria:
-
Patients aged ≥ 18 years old
-. Signed ICF, including patient's consent for genetic testing specimens from primary tumor and blood samples
-
Early HER2-negative BC (stages 2 and 3)
-
Compliance with at least 1 of the criteria for BRCA1/2 testing in accordance with the clinical guidelines of the Ministry of Health of the Russian Federation
-
Unknown BRCAm status or negative BRCAm PCR test
-
Performed surgical treatment (not more than 7 months before inclusion)
-. High risk of recurrence according to one or more criteria:
- incomplete pathomorphological response (in case of neoadjuvant therapy)
- CPS-EG 3 scale score 3 and more (in case of neoadjuvant therapy)
- presence of ≥ 4 metastatic lymph nodes in HR+ pts (in case of only adjuvant therapy)
- ≥pT2 or ≥pN1 in TNBC pts (in case of only adjuvant therapy)
- Any other high risk criterion according to investigators opinion
-
The presence of postoperative or biopsy FFPE
Exclusion Criteria:
- Participation in another clinical study with an investigational product during the last 3 months
- Confirmation that the subject was already included in this study before
- Absence of a written informed consent form; Data erroneously collected from subjects for which written consent is not available, will not be included in or will be deleted from the study database
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
The primary objective of this study is to determine the prevalence of germline and somatic BRCA1/2 mutations in high-risk early HER2-negative breast cancer
Tidsram: 3 years
|
The prevalence of germline and somatic BRCA1/2 mutations in high-risk early HER2-negative breast cancer will be presented as a number of missing and non-missing records, median, standard deviation, 95% confidence interval for median |
3 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
To describe treatment approaches of high-risk early HER2-negative breast cancer in routine practice in the general population, in the BRCAm and non-BRCAm population
Tidsram: 3 years
|
Demographics, clinical characteristics, and treatment approaches will be summarized using descriptive statistics. |
3 years
|
|
To determine invasive disease-free survival for high-risk early HER2-negative breast cancer in the general population, in the BRCAm and non-BRCAm population
Tidsram: 3 years
|
The Kaplan-Meier method will be used to estimate the median (95% CI) IDFS and OS for the total sample and all subgroups. Cumulative survival curves will be created using Kaplan-Meier analysis |
3 years
|
|
To determine 3-year OS for high-risk early HER2-negative breast cancer in the general population, in the BRCAm and non-BRCAm population
Tidsram: 3 years
|
The Kaplan-Meier method will be used to estimate the median (95% CI) IDFS and OS for the total sample and all subgroups. Cumulative survival curves will be created using Kaplan-Meier analysis |
3 years
|
|
To determine the prevalence of HRR mutations in HER2-negative breast cancer
Tidsram: 3 years
|
Testing the archived tumour specimen and blood for BRCA1/2m and HRRm status |
3 years
|
|
To determine invasive disease-free survival in the HRRm population (including BRCA1/2)
Tidsram: 3 years
|
Testing the archived tumour specimen and blood for BRCA1/2m and HRRm status |
3 years
|
|
To evaluate concordance between P53 expression and BRCAm
Tidsram: 3 years
|
Testing the archived tumour specimen and blood |
3 years
|
|
To assess the quality of life in patients with various types of adjuvant systemic therapy
Tidsram: 3 years
|
completed WHOQOL-BREF questionnaire will be assessed |
3 years
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- D133HR00030
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .